Evaluating stem cell transplantation for patients with peripheral T cell lymphoma
A Prospective Study of Consolidative Autologous Stem Cell Transplantation After First-line Therapy in Peripheral T Cell Lymphoma
This study is testing whether stem cell transplantation can help people with newly diagnosed peripheral T-cell lymphoma who are in remission after their first treatment feel better and live longer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Peking University Academic / other |
| Locations | 1 site (Beijing) |
| Trial ID | NCT04489264 on ClinicalTrials.gov |
What this trial studies
This observational study investigates the effectiveness of autologous stem cell transplantation (ASCT) in patients with newly diagnosed peripheral T-cell lymphoma who have achieved complete or partial remission after first-line therapy. The study aims to clarify the role of ASCT in improving clinical outcomes for these patients. By analyzing data from patients in remission, the research seeks to provide insights into the potential benefits of this treatment approach.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18-65 with a confirmed diagnosis of aggressive peripheral T-cell lymphoma who have achieved complete or partial remission after initial treatment.
Not a fit: Patients with indolent subtypes of T-cell lymphoma or those with specific conditions like mycosis fungoides or Sézary syndrome may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve treatment outcomes for patients with peripheral T cell lymphoma by identifying the benefits of stem cell transplantation.
How similar studies have performed: While the role of ASCT in peripheral T-cell lymphoma is not well defined, similar studies have explored its impact in other hematological malignancies, suggesting potential benefits but also indicating the need for further investigation.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with confirmed pathological diagnosis of aggressive PTCL * Age 18-65 years old * Achieving CR or PR after first-line therapy Exclusion Criteria: * Subtypes with a more indolent course, including precursor T/natural killer neoplasms, T-cell large granular lymphocytic leukemia, mycosis fungoides other than transformed mycosis fungoides, Sézary syndrome, and primary cutaneous CD30-positive disorders.
Where this trial is running
Beijing
- Beijing Cancer Hospital — Beijing, China (Recruiting)
Study contacts
- Principal investigator: Jun Zhu, Dr. — Peking University Cancer Hospital & Institute
- Study coordinator: Jun Zhu, Dr.
- Email: zhu-jun2017@outlook.com
- Phone: +86-13910333346
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.